{"created":"2023-05-15T15:03:25.754653+00:00","id":85932,"links":{},"metadata":{"_buckets":{"deposit":"de0ea00f-02b5-4b54-a1b5-4151ee7959d4"},"_deposit":{"created_by":1,"id":"85932","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"85932"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00085932","sets":["10:29"]},"author_link":["1039356","1039357","1039352","1039354","1039353","1039355"],"item_10005_date_7":{"attribute_name":"発表年月日","attribute_value_mlt":[{"subitem_date_issued_datetime":"2021-09-22","subitem_date_issued_type":"Issued"}]},"item_10005_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Uterine serous carcinoma (USC) is a rare aggressive type 2 endometrial carcinoma with high recurrence rate and dismal prognosis. Peritoneal metastasis is one of the common metastases of USC. Although trastuzumab, the anti-HER2 antibody, has shown benefit in the treatment of HER2 positive USC, the therapeutic efficacy is still limited. \nAntibody drug has been employed as the therapeutic option for cancer and provided benefits, however the acquired resistance of antibody-drug has been challenges to overcome for cancer treatment.\nTargeted alpha therapy (TAT) has high potential as a promising therapeutic option for metastasis. Astatine 211 (At-211) is one of the attractive α-particle emitters with an appropriate half-life and producible with cyclotron. We have demonstrated experimental TAT using [At-211]trastuzumab to preclinical mouse model with peritoneal metastasis of HER2 positive USC in order to investigate the therapeutic efficacy and toxicity. We will discuss the potential of TAT as a novel therapeutic option for antibody drug resistant peritoneal metastasis of HER2 positive USC.\n","subitem_description_type":"Abstract"}]},"item_10005_description_6":{"attribute_name":"会議概要（会議名, 開催地, 会期, 主催者等）","attribute_value_mlt":[{"subitem_description":"日本放射線影響学会第64回大会","subitem_description_type":"Other"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"李, 惠子"}],"nameIdentifiers":[{"nameIdentifier":"1039352","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"安康, 真由香"}],"nameIdentifiers":[{"nameIdentifier":"1039353","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"長谷川, 純崇"}],"nameIdentifiers":[{"nameIdentifier":"1039354","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Li, Huizi","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"1039355","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Mayuka, Anko","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"1039356","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Sumitaka, Hasegawa","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"1039357","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"conference object","resourceuri":"http://purl.org/coar/resource_type/c_c94f"}]},"item_title":"抗体薬抵抗性子宮体部漿液性がん腹膜播種に対する標的アルファ線治療","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"抗体薬抵抗性子宮体部漿液性がん腹膜播種に対する標的アルファ線治療"}]},"item_type_id":"10005","owner":"1","path":["29"],"pubdate":{"attribute_name":"公開日","attribute_value":"2022-04-08"},"publish_date":"2022-04-08","publish_status":"0","recid":"85932","relation_version_is_last":true,"title":["抗体薬抵抗性子宮体部漿液性がん腹膜播種に対する標的アルファ線治療"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T17:27:21.466961+00:00"}